A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2014
At a glance
- Drugs Balixafortide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Polyphor
- 10 Jun 2017 Biomarkers information updated
- 13 Jun 2014 Last checked against ClinicalTrials.gov.
- 22 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.